tbuckley/cabot-search huggingface dataset:
Algorithm of preoperative N-staging of non-small cell lung cancer
Authors: Andrey Petrov, Vadim Pischik, Marina Tlostanova, Mikhail Atyukov, Piotr Yablonsky
Journal: European Respiratory Journal (2013)

Objectives:  Accurate preoperative N-staging is a crucial point for management of non-small cell lung cancer (NSCLC). Aim of our study was to work out an algorithm of N-staging based not only on diagnostic value of different methods but also on long-term survival.   Material and Methods:  365 patients with potentially resectable NSCLC were included in a prospective study from 2003 till 2009. Patients were divided into two groups according to preoperative staging: group 1 (n=190) where both videomediastinoscopy (VM) and non-invasive procedures (CT, PET, evaluation of CYFRA 21-1) were used and group 2 (n=175), where only non-invasive methods were included in N-staging plan. Patients without preoperatively proven N2/N3 (n=324) underwent lung resections with systematic lymph nodes dissection.   Results:   Specificity, sensitivity, accuracy, PPV and NPV of VM (100%, 76%, 92%, 100% 90%) were significantly higher than those of CT (66%, 57%, 63%, 43%, 78%). High NPV and accuracy of PET (89% and 83%) and CYFRA 21-1 (86% and 78%) allow to exclude mediastinal metastasis in patients with peripheral cancer. The rate of postoperative N2 was lower in group 1 than in group 2 (10% vs 27%, p   Conclusions:  Proposed algorithm improves the accuracy of preoperative N-staging, that results in better long-term survival of operated patients.
AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs
Authors: Virginie Pichard, Nathalie Provost, Alexandra Mendes-Madeira, Lyse Libeau, Philippe Hulin, Kizito-Tshitoko Tshilenge, Marine Biget, Baptiste Ameline, Jack-Yves Deschamps, Michel Weber, Guylène Le Meur, Marie-Anne Colle, Philippe Moullier, Fabienne Rolling
Journal: Molecular Therapy (2016)

We previously reported that subretinal injection of AAV2/5 RK.cpde6β allowed long-term preservation of photoreceptor function and vision in the rod-cone dysplasia type 1 (rcd1) dog, a large animal model of naturally occurring PDE6β deficiency. The present study builds on these earlier findings to provide a detailed assessment of the long-term effects of gene therapy on the spatiotemporal pattern of retinal degeneration in rcd1 dogs treated at 20 days of age. We analyzed the density distribution of the retinal layers and of particular photoreceptor cells in 3.5-year-old treated and untreated rcd1 dogs. Whereas no rods were observed outside the bleb or in untreated eyes, gene transfer halted rod degeneration in all vector-exposed regions. Moreover, while gene therapy resulted in the preservation of cones, glial cells and both the inner nuclear and ganglion cell layers, no cells remained in vector-unexposed retinas, except in the visual streak. Finally, the retinal structure of treated 3.5-year-old rcd1 dogs was identical to that of unaffected 4-month-old rcd1 dogs, indicating near complete preservation. Our findings indicate that gene therapy arrests the degenerative process even if intervention is initiated after the onset of photoreceptor degeneration, and point to significant potential of this therapeutic approach in future clinical trials.
Response to Letter Regarding Article, “Recognition and Significance of Pathological T-Wave Inversions in Athletes”
Authors: Frédéric Schnell, Nathan Riding, Rory O’Hanlon, Pierre Axel Lentz, Erwan Donal, Gaelle Kervio, David Matelot, Guillaume Leurent, Stéphane Doutreleau, Laurent Chevalier, Sylvain Guerard, Mathew G. Wilson, François Carré
Journal: Circulation (2015)
Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer. Eur Urol 2015;68:167–8
Authors: Michele Greco, Salvatore Butticè, Carlo Magno, Sarah Onida
Journal: European Urology (2016)
Bcl-2 biomodulation with oblimersen sodium in combination with FOLFOX4 chemotherapy: A phase I study in metastatic colon carcinoma
Authors: T. A. Mays, A. C. Mita, C. Takimoto, D. Petro, M. J. Egorin, A. Patnaik, K. Papodopolous, E. Rowinsky, M. Goldston, A. Tolcher
Journal: Journal of Clinical Oncology (2005)

3158 Background: Bcl-2 overexpression occurs in 30–94% of human colorectal cancer (CRC) specimens, appears to be an early event in CRC tumorigenesis & correlates with a negative prognosis in Dukes C disease. In addition, bcl-2 overexpression confers a multi-drug resistant phenotype to tumor cells, including resistance to platinum. Oblimersen is an antisense oligonucleotide directed to the bcl-2 mRNA, & has demonstrated bcl-2 protein inhibition in vitro & in vivo. The objectives of this phase I trial were to: 1) determine the maximum tolerated dose; 2) characterize the main toxicities; 3) assess plasma pharmacokinetics (PKs); 4) determine relevant predictive biomarkers, & 5) document antitumor activity in CRC patients treated with escalating doses of oblimersen, in combination with fixed doses of 5-FU, oxaliplatin and leucovorin (FOLFOX4 regimen). Methods: Oblimersen was given as a continuous IV infusion (CIV) on days 1–7 and 15–21, and the FOLFOX4 regimen was administered on days 6–7 and 20–21 of a 28-day cycle. The protocol was subsequently amended to shorten the duration of oblimersen CIV to 5 days (days 1–5 and 15–20), while maintaining the same duration of FOLFOX4. Results: A total of 16 patients [7 male/9 female), median age 52 (range 37–76)] have received 34 cycles of the combination over 3 dose levels of oblimersen: 5 mg/kg/day x 7 days, 7 mg/kg/day x 7days, and 7 mg/kg/day x 5 days. Prolonged neutropenia resulting in dose delay > 14 days in cycle 1 was dose limiting in four patients, one each at dose levels one & two, & two at dose level three, respectively. Additionally, one patient treated at dose level 2 experienced treatment-related grade 3 fatigue Other toxicities were mild to moderate (grade 1–2) & included vomiting (3 patients), diarrhea (5 patients), oral mucositis (4 patients) & proteinuria (5 patients). One patient experienced a complete response after cycle 2, & 2 patients had partial responses in 13 evaluable patients. Mean [±SD] Oxaliplatin AUC, t1/2, and Cl were 3.7 [1.4] μg/mL*h, 14.9 [4.4] h, 220 [102] mL/min/m2, respectively. Conclusions: Although active, enhanced hematologic toxicity made FOLFOX 4 in combination with oblimersen not feasible at 7 mg/kg/day x 5 days. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genta, Sanofi Aventis, Genta
Case-Control Study of Antihypertensive and Diuretic Use by Women With Malignant and Benign Breast Lesions Detected in a Mammography Screening Program
Authors: Roger R. Williams, M.D., Manning Feinleib, M.D., Dr. P.H.
 5, Robert J. Connor, Dr. Eng., Nancy L. Stegens, B.A.
Journal: JNCI Journal of the National Cancer Institute (1978)

A significant but low-level association (relative odds, 2.0; P less than 0.05) was observed between the occurrence of breast cancer and the use of rauwolfia derivatives for 5 or more years in the study of 481 breast cancer cases and 1,268 controls from a joint national mammography screening project of the National Cancer Institute and the American Cancer Society. This association was confined to women over age 50 years who were also heavier than average. No confounding effects could be held responsible for this association after adjustment was made for variables such as presence of hypertension, weight, age at first pregnancy, and other breast cancer risk factors. Other antihypertensive and diuretic drugs as well as multiple drug use also exhibited some suggestive associations with breast cancer. Another group of 421 women with benign lesions at breast biopsy were also compared to the 1,268 controls. They showed a significant association between benign lesions and use of thiazides for 5 or more years (relative odds, 2.4; P less than 0.001) whether employed to treat edema or hypertension. Other antihypertensive and diuretic agents also seemed to show this association, but most of them were being used together with thiazides.
The increasing incidence of HIV-associated multicentric Castlemans disease
Authors: A. Bazeos, T. Powles, J. Stebbing, S. Mandalia, M. Bower
Journal: Journal of Clinical Oncology (2008)

7085 Background: Multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) are causally related to infection with human herpesvirus-8 (HHV-8). In HIV cohorts with access to highly active antiretroviral therapy (HAART) the incidence of KS is falling; however the incidence of MCD in this setting has not previously been described. Methods: We calculated the incidence of HIV-MCD from a prospective database of HIV patients with 52,035 years of follow up, using HIV-KS incidence as a control. The incidence in specific time periods related to the introduction of HAART was calculated. Results: The event rate for HIV-MCD was 16.3 (95% confidence interval (CI): 10.2–24.2) /10,000 patient years of follow up. The incidence of HIV-MCD in the pre-HAART (1983–1996), initial HAART (1997–2001) and HAART (2002–2007) eras were 2.3 (95% CI: 0.1–12.8), 11.1 (95% CI: 3.6–26.0) and 31.3 (95% CI: 18.2–50.1) respectively, representing a statistically significant increase over time (p <0.05). This incidence was not related to the degree of immunosuppression, the duration of HIV infection, gender, prior AIDS or HAART use. This is in contrast to the incidence of KS, which was commoner in men, fell dramatically with HAART and decreased with improved immune function. Conclusions: Unlike KS, the incidence of HIV-MCD does not appear related to the degree of immunosuppression or gender. The incidence of HIV-MCD is increasing, and this rise is not related to HAART use. No significant financial relationships to disclose.
Abstract 14564: Bone Morphogenetic Protein Receptor Type II-Associated Heritable Pulmonary Arterial Hypertension is Associated with Fatty Acid Oxidation Defects and Cardiac Steatosis
Authors: Evan Brittain, Josh Fessel, Kelly Fox, Lawrence Sweetman, Rizwan Hamid, Eric Austin, James West, Anna Hemnes
Journal: Circulation (2012)

Background: We have previously demonstrated in endothelial cells that impaired fatty acid oxidation(FAO) and increased glycolysis are direct consequences of mutation in Bone Morphogenetic Protein R...
Autoradiographic Localization of Tissue-Bound Tritiated 7,12-Dimethylbenz[a]anthracene in Mouse Skin 24 and 48 Hours After Single Application2
Authors: Takashi Nakai, Philippe Shubik
Journal: JNCI Journal of the National Cancer Institute (1964)

Journal Article Autoradiographic Localization of Tissue-Bound Tritiated 7,12-Dimethylbenz[a]anthracene in Mouse Skin 24 and 48 Hours After Single Application Get access Takashi Nakai, Takashi Nakai Search for other works by this author on: Oxford Academic PubMed Google Scholar Philippe Shubik Philippe Shubik Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 33, Issue 5, November 1964, Pages 887–891, https://doi.org/10.1093/jnci/33.5.887 Published: 01 November 1964 Article history Received: 20 May 1964 Published: 01 November 1964
A tracking and feedback registry to reduce disparities in breast cancer care
Authors: N. Bickell, K. Shastri, K. Fei, S. Oluwole, H. Godfrey, A. Srinivasan, K. Hiotis, A. Guth
Journal: Journal of Clinical Oncology (2008)

6512 Background: Despite effective adjuvant treatment for early stage breast cancer, women do not always receive it, particularly, minority women. Adjuvant underuse occurs more commonly among women who do not see a medical oncologist despite surgeons' referral request. To reduce underuse of adjuvant treatment due to failed connections, we tracked and provided information to surgeons about whether their breast cancer patients connected with an oncologist. Methods: We compared oncology referral rates and underuse among pre- (N=677) and intervention (N=300) patients undergoing breast cancer surgery at 6 NYC hospitals. Each surgeon chose staff to verify patient eligibility; staff and patients identified upcoming oncology appointment sites and times. Following scheduled visits, oncologists were called to assess completed consultations & these data were fed back to surgeons. Six months later, we abstracted in- & outpatient charts. We compared rates of: completed oncology consultations and underuse of radiotherapy after breast conserving surgery, of chemotherapy for ER negative and hormonal therapy for ER positive tumors >1cm pre- and intervention oncology referral & overall adjuvant therapy underuse and rates between women with newly diagnosed early-stage breast cancer. Results: Completed oncology consultations increased (83% to 97%; p<0.0001) and underuse of adjuvant treatment decreased (21% to 14%; p<0.001), specifically, underuse of chemotherapy (22% to 11%; p=0.05) and hormonal therapy (20% to 8%; p=0.0004). Among black and Hispanic women, underuse of radiotherapy significantly decreased (23% to 10%; p=0.02). Models adjusting for hospital, age, stage, insurance & comorbidity found the intervention increased rates of oncology consultation (OR=5.33; 95%CI: 2.68–10.60), and reduced adjuvant underuse (OR= 0.62; 95%CI: 0.42–0.93). Minority race was no longer a risk factor for an oncology consultation (OR=1.20; 95%CI: 0.69–2.08) or underuse of adjuvant therapy (OR= 1.13; 95%CI: 0.73–1.75). Conclusions: A tracking and feedback registry which closes the referral loop between surgeons and oncologists appears to improve rates of medical oncology consultation, reduces rates of adjuvant treatment underuse and eliminates the racial disparity in treatment. No significant financial relationships to disclose.
Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up
Authors: Brian Leber, Francisco Cervantes, Nelson Spector, Jeffrey H. Lipton, Gabriel Etienne, Ricardo Pasquini, Nelma Christina Clementino, Agnès Guerci-Bresler, Donna Forrest, Anthony P. Schwarer, Sandip Acharya, LaTonya Collins, Tomasz Szczudlo, Timothy P. Hughes
Journal: Blood (2013)
RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer
Authors: S. J. Wong, K. Winter, N. J. Meropol, R. Anne, L. A. Kachnic, A. Rashid, J. C. Watson, E. P. Mitchell, J. Pollock, R. J. Lee, C. G. Willett
Journal: Journal of Clinical Oncology (2008)

4021 Background: Preoperative chemoradiation for distal rectal cancer is an effective treatment strategy in which achievement of pathologic complete response (pCR) may be associated with a favorable prognosis. Methods: A randomized phase II trial evaluated preoperative RT (50.4 Gy in 1.8 Gy fractions) with (1) concurrent capecitabine (1,200 mg/m2/d orally M-F during RT) and irinotecan (50 mg/m2 IV weekly x 4 doses) (Arm 1), and with (2) concurrent capecitabine (1,650 mg/m2/d orally M-F during RT) and oxaliplatin (50 mg/m2 IV weekly x 5 doses) (Arm 2) in patients with clinical stage T3 or T4 rectal cancer < 12 cm from the anal verge. Surgery was performed 4–8 weeks following completion of chemoradiation. Four to 6 weeks after surgery, adjuvant chemotherapy (oxaliplatin 85 mg/m2; leucovorin 400 mg/m2 IV over 2 hours; 5-FU 400 mg/m2 IV bolus; 5- FU 2,400 mg/m2/46 hr infusion) was administered every 2 weeks x 9 cycles. The primary endpoint was pCR rate. Forty eight evaluable patients were required for each arm. Either treatment arm would be considered for further study if there were at least 9 pCRs out of 48 evaluable patients. Results: Of 146 accrued patients, 101 were analyzable after initial temporary closure and amendment (final regimens noted above) for excessive GI toxicity. Patient characteristics were similar for both arms. Median age was 57 years; 68% male (69/101); 88% T3 (89/101). Following chemoRT, tumor downstaging was 56% (27/48) and 58% (28/48), and nodal downstaging was 36% (12/33) and 33% (9/27), for Arms 1 and 2, respectively. The pCR rate for Arm 1 was 10% (5/48) and for Arm 2 was 21% (10/48). Preop chemoRT grade 3/4 hematologic toxicity was 8% (6/49) and 4% (2/52), and preop chemoRT grade 3/4 non-hematologic toxicity was 24% (12/49) and 29% (15/52) for Arms 1 and 2, respectively (CTCAE v3.0). The predominant non-hematologic toxicity was GI. Conclusions: Preoperative radiation with concurrent capecitabine plus oxaliplatin for distal rectal cancer has manageable toxicity and with 10/48 pCRs, this regimen warrants further study. This combination will become the backbone for the next RTOG rectal cancer study examining the potential benefit of intensity modulated radiation in reducing GI morbidity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen, Genentech, ImClone, Pfizer, sanofi-aventis Pfizer, Roche, sanofi-aventis Roche, sanofi-aventis
Clinical magnetic resonance angiography: Edited by C M Anderson, R R Edelman and P A Turski. (Pp 498; $170.50.) New York: Raven Press, 1992. ISBN 0-7817-0094-9
Authors: G. Olivecrona, K. Reynisson, S B. Olsson
Journal: Cardiovascular Research (1995)

Clinical magnetic resonance angiography: Edited by C M Anderson, R R Edelman and P A Turski. (Pp 498; $170.50.) New York: Raven Press, 1992. ISBN 0-7817-0094-9 Get access Clinical Magnetic Resonance Angiography. Edited by Anderson C M Edelman R R Turski P A. (Pp 498 $170.50.) New York: Raven Press, 1992). ISBN 0-7817-0094-9. Göran Olivecrona, Göran Olivecrona Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Kristbjörn Reynisson, Kristbjörn Reynisson Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar S Bertil Olsson S Bertil Olsson Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 2, February 1995, Pages 293–294, https://doi.org/10.1016/S0008-6363(95)90019-5 Published: 01 February 1995
A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis
Authors: E. P. Mitchell, M. E. LaCouture, H. Shearer, N. Iannotti, B. Piperdi, M. V. Pillai, F. Xu, M. Couture, M. Yassine
Journal: Journal of Clinical Oncology (2008)

15007 Background: Pmab, a fully human monoclonal antibody against the epidermal growth factor receptor, is approved in the US for the tx of pts with refractory mCRC. This randomized study examined differences between pre-emptive and reactive skin tx for ST associated with pmab therapy. Methods: Pts with unresectable mCRC and disease progression whose 1st-line tx with CT± bevacizumab failed were enrolled. Pts received Q2W FOLFIRI+pmab (6.0mg/kg) or Q3W irinotecan+pmab (9.0mg/kg). Within cohorts, pts were randomized 1:1 to pre-emptive ST tx (24 hrs prior to 1st pmab dose, daily through wk 6) or reactive tx (after ST developed). ST tx included use of skin moisturizers, sunscreen, topical corticosteroids, and oral doxycycline. The primary endpoint was incidence of specific ≥ grade (gr) 2 ST during the 6-wk skin tx period. This early analysis assessed pooled safety (data cutoff 06/07). Results: Of 58 pts with available data, 32 pts and 26 pts received the Q2W and Q3W regimens, respectively. Pts received a median of 7.5 (Q2W cohort) and 4.0 (Q3W cohort) doses of pmab and CT. Tx-related adverse events (AEs) were seen in 95% of pts; 62% had gr 3/4. AEs of interest are shown (table). Pmab dose reductions occurred in 6 pts (10%) due to ST; 19 pts had serious AEs; 2 pts ended the study because of an AE. Ten pts (31%) in the Q2W cohort and 1 pt (4%) in the Q3W cohort had an objective response to pmab. Planned enrollment of 95 pts has been completed; efficacy outcomes (pre-emptive vs reactive ST tx and objective response) by KRAS status for all pts will be presented. Conclusions: No safety issues were identified in this early analysis of pts receiving pmab + irinotecan-based CT. Pooled Analysis of Adverse Events (n = 58) AE Any grade, n (%) ≥ Grade 3, n (%) Skin Toxicity 51 (88) 13 (22) Infections * 42 (72) 13 (22) Diarrhea 40 (69) 8 (14) Nausea 31 (53) 4 (7) Neutropenia 16 (28) 9 (16) Dehydration 13 (22) 7 (12) Hypomagnesemia 10 (17) 3 (5) Deep venous thrombosis 2 (3) 2 (3) Pulmonary embolism 0 (0) 0 (0) Per MedDRA; grading based on CTCAEv3, modified for ST. * Includes rash pustular and paronychia No significant financial relationships to disclose.
Evaluation of heterogeneities in baseline risks and treatment effects among hospitals: Additional result of JCOG9912 phase III trial for advanced gastric cancer
Authors: Y. Kurokawa, T. Yamaguchi, K. Yoshimura, S. Yamamoto, N. Boku, K. Shirao, A. Ohtsu, H. Fukuda
Journal: Journal of Clinical Oncology (2008)

6638 Background: JCOG9912 phase III trial demonstrated the treatment effect of irinotecan plus cisplatin (CP) regimen or S-1 regimen compared with 5-FU regimen for advanced gastric cancer (ASCO2007 Abs#LBA4513). As written in international statistical guideline (ICH-E9), it is important to examine the variations among hospitals in the baseline risks of standard 5-FU regimen for standardization of cancer treatment and also in the treatment effects of experimental CP or S-1 regimen for evaluating the generalizability of the outcomes of JCOG9912 trial. Methods: Mixed effect models were applied to data of survival and adverse events (AE) for 658 (5-FU: 218, CP: 221, S-1: 219) patients from 22 Japanese hospitals. After adjustment with nine prognostic factors, the baseline risk of 5-FU regimen and the treatment effect of CP or S-1 regimen were estimated at each hospital. Spearman's correlation coefficients between the estimated differences and hospital factors were also estimated. Results: In the baseline risks of 5-FU regimen, the median OS and PFS were estimated at 8.3 to 13.3 months and 2.4 to 3.4 months, respectively. The treatment effect of CP or S-1 regimen was estimated as shown in Table. As for the hospital factors correlated with estimated differences, physician's experience in oncology and AE in CP regimen (r=-0.46) and the number of physicians and AE in S-1 regimen (r=-0.48) were significantly correlated. There were no significant correlations with hospital factors other than these two factors. Conclusions: The hospitals participated in JCOG9912 phase III trial had some variation in the baseline risks of 5- FU regimen. The final result of JCOG9912 trial seemed to be generalizable to the target populations, because there was little heterogeneity in the treatment effect of CP or S-1 regimen. The ranges of estimated relative risks of CP or S-1 regimen to 5-FU regimen among 22 hospitals Regimen Hazard ratio for OS (Extension of median OS) Hazard ratio for PFS (Extension of median PFS) Risk ratio for AE (Increase of AE proportion) CP 0.81 to 0.91 (+1.1 to +2.5 mo) 0.62 to 0.82 (+0.6 to +1.7 mo) 1.90 to 1.94 (+38.8 to +40.5%) S-1 0.75 to 0.80 (+2.7 to +3.6 mo) 0.77 to 0.90 (+0.3 to +0.8 mo) 0.94 to 0.96 (-2.6 to -1.7%) No significant financial relationships to disclose.